ReviewCardiovascular endocrinology & metabolism2018
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists.
Review in Cardiovascular endocrinology & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.Diabetes, obesity & metabolism · 2026Trial
- Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it.Obesity pillars · 2026Review
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.JACC. Advances · 2026Article
- Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.Cureus · 2024Review
- Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.International journal of molecular sciences · 2024Article
- The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Repurposing Antidiabetic Drugs for Cardiovascular Disease.Frontiers in physiology · 2020Review
- Recent advances in understanding the role of glucagon-like peptide 1.F1000Research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2 diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current treatments are effective at reducing hyperglycaemia. GLP-1 exerts specific actions on the cardiovascular system in both healthy individuals and patients with cardiovascular pathology, and GLP-1 therapies have improved the cardiovascular profile of diabetic patients. GLP-1 exerts its action by binding to its receptor (GLP-1 receptor) at the cell surface. Mechanistically, it is not clear how GLP-1 therapies exert beneficial effects on the cardiovascular system. It is difficult to arrive at any conclusions on the ability of GLP-1 receptor agonism to reduce cardiovascular disease from animal/human studies because of varying experimental designs. This review highlights recent findings from long-term human GLP-1 therapy studies, and summarizes postulated mechanisms as to how GLP-1 receptor agonism may alleviate cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.